文献速递神经肿瘤功能神经外科

清醒开颅联合经皮质运动诱发电位监测预测脑胶质瘤术后运动功能

Awake craniotomy with transcortical motor evoked potential monitoring for resection of gliomas within or close to motor-related areas: validation of utility for predicting motor function.
PubMed 文献 · J Neurosurg · 2021-09-24

本研究纳入2000年4月至2020年5月治疗的95例位于或邻近运动相关区(不限于中央前回)的胶质瘤患者,均在清醒开颅下结合术中自主运动(IVM)与经皮质运动诱发电位(MEP)监测切除肿瘤;术后6个月运动功能与IVM、MEP下降幅度(≤或>50%)、年龄、术前运动障碍、切除程度及术后MRI缺血改变显著相关,验证了联合监测及100 µV界值的预测价值。

要点

  • IVM与经皮质MEP联合监测可预测术后6个月运动功能,不限于中央前回胶质瘤
  • IVM下降且MEP下降>50%者83%(19/23)出现运动功能下降

核心结论

  • 清醒开颅中IVM联合经皮质MEP监测可预测位于或邻近运动相关区(不限于中央前回)胶质瘤患者术后6个月的运动功能。
  • MEP监测中100 µV界值的实用性得到验证。

研究设计与样本

  • 回顾性纳入2000年4月至2020年5月治疗的95例位于或邻近运动相关区的胶质瘤患者。
  • 所有肿瘤均在清醒开颅下经IVM监测与经皮质MEP监测切除。
  • 术后运动功能分为无变化或下降,下降再分为轻度、中度、重度,中度与重度定义为影响日常生活。

主要发现

  • 术后6个月运动功能:无变化71例、轻度18例、中度5例、重度1例。
  • 术后6个月运动功能与IVM(p < 0.0001)、经皮质MEP下降(≤或>50%)(p < 0.0001)、年龄、术前运动功能障碍、切除程度及术后MRI缺血改变显著相关。
  • IVM下降且MEP下降≤50%的34例中5例(15%)术后6个月为轻度运动障碍。
  • IVM下降且MEP下降>50%的23例中19例(83%)运动功能下降,包括轻度13例、中度5例、重度1例;6例中度或重度障碍者MEP最低值均<100 µV。

关键数值与推荐

  • 运动功能评估时点为术后6个月,分为无变化、轻度、中度、重度,中度与重度为影响日常生活。
  • MEP下降幅度以50%为分组界值(≤50%与>50%)。
  • MEP最低值<100 µV见于6例中度或重度运动障碍患者。

临床怎么用

  • 对位于或邻近运动相关区(不限于中央前回)的胶质瘤,可在清醒开颅下联合IVM与经皮质MEP监测辅助预测术后6个月运动功能。
  • IVM无变化提示术后运动功能可能无变化;IVM下降且MEP下降>50%提示运动功能下降风险较高。
  • MEP最低值<100 µV者需关注中重度运动障碍风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors previously showed that combined evaluation of changes in intraoperative voluntary movement (IVM) during awake craniotomy and transcortical motor evoked potentials (MEPs) was useful for predicting postoperative motor function in 30 patients with precentral gyrus glioma. However, the validity of the previous report is limited to precentral gyrus gliomas. Therefore, the current study aimed to validate whether the combined findings of IVM during awake craniotomy and transcortical MEPs were useful for predicting postoperative motor function of patients with a glioma within or close to motor-related areas and not limited to the precentral gyrus. METHODS: The authors included 95 patients with gliomas within or close to motor-related areas who were treated between April 2000 and May 2020. All tumors were resected with IVM monitoring during awake craniotomy and transcortical MEP monitoring. Postoperative motor function was classified into four categories: "no change" or "declined," the latter of which was further categorization as "mild," "moderate," or "severe." The authors defined moderate and severe deficits as those that impact daily life. RESULTS: Motor function 6 months after surgery was classified as no change in 71 patients, mild in 18, moderate in 5, and severe in 1. Motor function at 6 months after surgery significantly correlated with IVM (p < 0.0001), transcortical MEPs (decline ≤ or > 50%) (p < 0.0001), age, preoperative motor dysfunction, extent of resection, and ischemic change on postoperative MRI. Thirty-two patients with no change in IVM showed no change in motor function at 6 months after surgery. Five of 34 patients (15%) with a decline in IVM and a decline in MEPs ≤ 50% had motor dysfunction with mild deficits 6 months after surgery. Furthermore, 19 of 23 patients (83%) with a decline in IVM and decline in MEPs > 50% had a decline in motor function, including 13 patients with mild, 5 with moderate, and 1 with severe deficits. Six patients with moderate or severe deficits had the lowest MEP values, at < 100 µV. CONCLUSIONS: This study validated the utility of combined application of IVM during awake craniotomy and transcortical MEP monitoring to predict motor function at 6 months after surgery in patients with a glioma within or close to motor-related areas, not limited to the precentral gyrus. The authors also validated the usefulness of the cutoff value, 100 µV, in MEP monitoring.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Saito T, Muragaki Y, Tamura M, et al. Awake craniotomy with transcortical motor evoked potential monitoring for resection of gliomas within or close to motor-related areas: validation of utility for predicting motor function. J Neurosurg. 2021. PMID: 34560661. doi:10.3171/2021.3.JNS21374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。